Affidea Group lifts add-on term B to €170 million, sets OID at 98.5

By Sara Rosenberg

New York, May 26 – Affidea Group BV (Celeste BidCo BV) upsized its fungible add-on first-lien term loan B due June 2029 to €170 million from €150 million and finalized the original issue discount at 98.5, versus talk at launch in the 98 area (+/- 0.5 point), according to a market source.

Pricing on the add-on term loan is Euribor plus 500 basis points with a 0% floor, in line with pricing on the company’s existing €600 million term loan B.

BNP Paribas, KKR Capital Markets and Goldman Sachs are the joint global coordinators and physical bookrunners on the deal that is scheduled to launch with a lender call at 6 a.m. ET on Tuesday. UniCredit Bank is the agent.

Recommitments were scheduled to be due at 7 a.m. ET on Friday, the source added.

Proceeds will be used to fund bolt-on acquisitions, to repay revolving credit facility borrowings, for general corporate purposes and to pay related fees and expenses.

Groupe Bruxelles Lambert is the sponsor.

Affidea is a Netherlands-based provider of integrated community health care, offering diagnostic imaging, outpatient services, lab services and cancer care.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.